AbbVie Inc.
ABBV · CIK 0001551152 · NYSE · Healthcare (Pharmaceutical Preparations)
Overview — AbbVie Inc.
Revenue (TTM)
$64.39B
Net Income (TTM)
$6.32B
Total Assets
$135.12B
Total Debt
—
Pros
- Strong free cash flow generation
- Operating cash flow comfortably exceeds reported net income
Cons
- Negative return on equity (TTM) — the company is unprofitable
Chart
No price data yet — run npm run ingest:prices in apps/api.
Revenue & Net Income
RevenueNet Income
Peers
Sector: Healthcare. Sector is derived from SEC's SIC code, not GICS. Click a column to sort.
| Company | Market Cap ▼ | Revenue (TTM) | Net Income (TTM) | Net Margin | ROE | Debt/Equity |
|---|---|---|---|---|---|---|
| JNJ JOHNSON & JOHNSON | $660.42B | $99.33B | $16.09B | 16.2% | 19.7% | 0.44 |
| ABBV AbbVie Inc. | — | $64.39B | $6.32B | 9.8% | -106.4% | — |
| MRK Merck & Co., Inc. | — | $66.57B | $3.17B | 4.8% | 7.6% | 1.28 |
| PFE PFIZER INC | — | $63.70B | $4.36B | 6.8% | 5.1% | 0.71 |
| MMM 3M CO | — | $25.25B | $3.58B | 14.2% | 85.9% | 3.01 |
Quarterly results
| Line item | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.93B | $14.30B | $12.31B | $14.46B | $14.46B | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B | $16.99B |
| Net Income | $1.78B | $822.00M | $1.37B | $1.37B | $1.56B | -$22.00M | $1.29B | $941.00M | $188.00M | $1.82B | $697.00M | $3.62B |
| Operating Cash Flow | — | — | $4.04B | — | — | — | $1.64B | — | — | — | $3.83B | — |
Profit & Loss
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B | $64.39B |
| Net Income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.55B | $11.85B | $4.87B | $4.29B | $4.23B | $6.32B |
Balance Sheet
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | — | — | — | — | — | — | — | — | — | — | $135.12B |
| Total Liabilities | — | — | — | — | — | — | — | — | — | — | — |
| Total Equity | — | — | — | — | — | — | — | — | — | — | -$5.93B |
| Total Debt | — | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | — | — | — | — | — | — | — | — | — | 1,767,117,285 |
Cash Flow
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | — | $9.96B | $13.43B | $13.32B | $17.59B | $22.78B | $24.94B | $22.84B | $18.81B | $19.03B | $21.22B |
| Capex | $479.00M | $529.00M | $638.00M | $552.00M | $798.00M | $787.00M | $695.00M | $777.00M | $974.00M | $1.21B | $1.24B |
Ratios
Profitability
| Ratio | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.6% | 20.4% | 9.0% | 7.6% | 6.9% | 9.8% |
| Return on equity | — | — | — | — | — | — | — | — | — | — | -106.4% |
| Return on assets | — | — | — | — | — | — | — | — | — | — | 4.7% |
| Return on capital employed (ROCE) | — | — | — | — | — | — | — | — | — | — | 18.0% |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| FCF margin | — | 33.4% | 39.0% | 38.4% | 36.7% | 39.1% | 41.8% | 40.6% | 31.7% | 29.1% | 31.0% |
Working capital
| Ratio | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | — | — | — | — | — | — | — | — | — | — | 78d |
| Inventory days | — | — | — | — | — | — | — | — | — | — | 102d |
| Payable days | — | — | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | — | — | — | — | — | — | — | — | — | — | — |
| Working capital days | — | — | — | — | — | — | — | — | — | — | -45d |
Investors
US filings have no equivalent to India's Promoter/FII/DII shareholding-pattern disclosure. Shown below are the closest real US sources: Form 4 insider transactions and Form 13F institutional holders (matched by issuer name, not CUSIP — a few companies, especially ones that changed their legal name, may be incomplete).
Institutional Holders
No data yet — run npm run ingest:institutions in apps/api.
Insider Trades
| Person | Relationship | Date | Type | Shares | Price |
|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 8/14/2026 | Option exercise | 32,710 | $79.02 |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 8/14/2026 | Sale | 32,710 | $250.00 |
| FALK THOMAS J | 5/8/2026 | Grant/Award | 1,118 | — | |
| WADDELL FREDERICK H | 5/8/2026 | Grant/Award | 1,118 | — | |
| Roberts Rebecca B | 5/8/2026 | Grant/Award | 1,118 | — | |
| RAPP EDWARD J | 5/8/2026 | Grant/Award | 1,118 | — | |
| Quaggin Susan E | 5/8/2026 | Grant/Award | 1,118 | — | |
| MEYER MELODY B | 5/8/2026 | Grant/Award | 1,118 | — | |
| Hart Brett J | 5/8/2026 | Grant/Award | 1,118 | — | |
| FREYMAN THOMAS C | 5/8/2026 | Grant/Award | 1,118 | — | |
| Davis Jennifer L. | 5/8/2026 | Grant/Award | 1,118 | — | |
| BURNSIDE WILLIAM H.L. | 5/8/2026 | Grant/Award | 1,118 | — | |
| AUSTIN ROXANNE S | 5/8/2026 | Grant/Award | 1,118 | — | |
| Purdue David Ryan | SVP, Controller | 3/4/2026 | Sale | 5,230 | $233.56 |
Documents
- 10-Q — filed 8/3/20260001551152-26-000026
- 10-Q — filed 5/8/20260001551152-26-000017
- 10-K — filed 2/20/20260001551152-26-000008
- 10-Q — filed 11/4/20250001551152-25-000049
- 10-Q — filed 8/4/20250001551152-25-000040
- 10-Q — filed 5/9/20250001551152-25-000029
- 10-K — filed 2/14/20250001551152-25-000020
- 10-Q — filed 11/4/20240001551152-24-000040
- 10-Q — filed 8/7/20240001551152-24-000031
- 10-Q — filed 5/3/20240001551152-24-000020
- 10-K — filed 2/20/20240001551152-24-000011
- 10-Q — filed 11/6/20230001551152-23-000045
- 10-Q — filed 8/7/20230001551152-23-000033
- 10-Q — filed 5/5/20230001551152-23-000023
- 10-K — filed 2/17/20230001551152-23-000011
- 10-Q — filed 11/4/20220001551152-22-000045
- 10-Q — filed 8/4/20220001551152-22-000030
- 10-Q — filed 5/6/20220001551152-22-000017
- 10-K — filed 2/18/20220001551152-22-000007
- 10-Q — filed 11/2/20210001551152-21-000031
- 10-Q — filed 8/2/20210001551152-21-000025
- 10-Q — filed 5/7/20210001551152-21-000016
- 10-K — filed 2/19/20210001551152-21-000008
- 10-Q — filed 11/4/20200001551152-20-000032
- 10-Q — filed 8/4/20200001551152-20-000023
- 10-Q — filed 5/8/20200001551152-20-000015
- 10-K — filed 2/21/20200001551152-20-000007
- 10-Q — filed 11/6/20190001551152-19-000030
- 10-Q — filed 8/5/20190001551152-19-000023
- 10-Q — filed 5/3/20190001551152-19-000016
- 10-K — filed 2/27/20190001551152-19-000008
- 10-Q — filed 11/7/20180001551152-18-000042
- 10-Q — filed 8/7/20180001551152-18-000032
- 10-Q — filed 5/4/20180001551152-18-000025
- 10-K — filed 2/16/20180001551152-18-000014
- 10-Q — filed 11/7/20170001551152-17-000035
- 10-Q — filed 8/7/20170001551152-17-000025
- 10-Q — filed 5/5/20170001551152-17-000016
- 10-K — filed 2/17/20170001551152-17-000004
- 10-Q — filed 11/7/20160001551152-16-000005
- 10-Q — filed 8/5/20160001104659-16-137453
- 10-Q — filed 5/6/20160001104659-16-118639
- 10-K — filed 2/19/20160001047469-16-010239
- 10-Q — filed 11/6/20150001104659-15-076607
- 10-Q — filed 8/7/20150001104659-15-057641
- 10-Q — filed 5/8/20150001104659-15-036257
- 10-K — filed 2/20/20150001047469-15-000995
- 10-Q — filed 11/7/20140001104659-14-078391
- 10-Q — filed 8/7/20140001104659-14-058340
- 10-Q — filed 5/9/20140001104659-14-036968
- 10-K — filed 2/21/20140001047469-14-001154
- 10-Q — filed 11/12/20130001104659-13-083686
- 10-Q — filed 8/9/20130001104659-13-062262
- 10-Q — filed 5/8/20130001104659-13-038917